Therapeutic strategies for Helicobacter pylori in Colombia
DOI:
https://doi.org/10.21615/cesmedicina.6224Keywords:
Helicobacter pylori, treatment, gastritis, stomach neoplasms, ColombiaAbstract
The wide spectrum of diseases caused by Helicobacter pylori infection requires a timely diagnosis and a highly effective treatment, reducing the risk of morbidity and increasing the probability of eradication. There are several therapies that are supported in the literature, therefore, its advantages and limitations, including our local resistances, must be known to select the best option. This article reviews the most widely used treatment regimens and offers guidelines for the management and follow-up of patients with Helicobacter pylori infection in Colombia.
Downloads
References
Porras C, Nodora J, Sexton R, Ferreccio C, Jimenez S, Dominguez RL, et al. Epidemiology of Helicobacter pylori infection in six Latin American countries (SWOG Trial S0701). Cancer Causes Control. 2013;24(2):209–15.
Graham D. Helicobacter pylori update: Gastric Cancer, Reliable Therapy, and Possible Benefits. Gastroenterology. 2015;148(4):719-731.e3.
Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. 2021.
Bauerfeind P, Garner R, Dunn BE, Mobley HL. Synthesis and activity of Helicobacter pylori urease and catalase at low pH. Gut. 1997;40(1):25–30.
Perry S, de la Luz Sanchez M, Yang S, Haggerty TD, Hurst P, Perez-Perez G, et al. Gastroenteritis and transmission of Helicobacter pylori infection in households. Emerg Infect Dis. 2006;12(11):1701–8.
Kotilea K, Bontems P, Touati E. Epidemiology, diagnosis and risk factors of Helicobacter pylori Infection. Adv Exp Med Biol. 2019;1149:17–33.
Otero R W, Trespalacios R AA, Otero PL, Vallejo MT, Torres Amaya M, Pardo R et al . Guía de práctica clínica para el diagnóstico y tratamiento de la infección por Helicobacter pylori en adultos. Rev Colombde Gastroent. 2015. (30.1): 17-33.
Patel KA, Howden CW. Update on the diagnosis and management of Helicobacter pylori infection in adults. J Clin Gastroenterol. 2015;49(6):461–7.
Chey WD, Leontiadis GI, Howden CW, Moss SF. Correction: ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J Gastroenterol. 2018;113(7):1102.
Malfertheiner P, Megraud F, O’Morain CA, Gisbert JP, Kuipers EJ, Axon AT, et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017;66(1):6–30.
Otero R W, Gómez Z M, Otero P L, Trespalacios R A. Helicobacter pylori: ¿cómo se trata en el 2018? Rev Gastroenterol Peru. 2018;38(1):54–63.
Crowe SE. Helicobacter pylori infection. Reply. N Engl J Med. 2019;381(6):588–9.
W DB, G T. Review: The Best Therapy for Helicobacter pylori Infection: Should efficacy or side-effect profile determine our choice? Scand J of Gastroent. 1995;30(5).
Gisbert JP, González L, Calvet X, García N, López T, Roqué M, et al. Proton pump inhibitor, clarithromycin and either amoxycillin or nitroimidazole: a meta-analysis of eradication of Helicobacter pylori: a meta-analysis of h. pylori eradication therapy. Aliment Pharmacol Ther. 2000;14(10):1319–28.
Luther J, Higgins PDR, Schoenfeld PS, Moayyedi P, Vakil N, Chey WD. Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability. Am J Gastroenterol. 2010;105(1):65–73.
Wang Z, Wu S. Doxycycline-based quadruple regimen versus routine quadruple regimen for rescue eradication of Helicobacter pylori: an open-label control study in Chinese patients. Singapore Med J. 2012;53(4):273–6.
Venerito M, Krieger T, Ecker T, Leandro G, Malfertheiner P. Meta-analysis of bismuth quadruple therapy versus clarithromycin triple therapy for empiric primary treatment of Helicobacter pylori Infection. Digestion. 2013;88(1).
Fischbach L, Evans EL. Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori: meta-analysis: effect of antibiotic resistance on treatments for H. pylori. Aliment Pharmacol Ther. 2007;26(3):343–57.
Gisbert JP, Calvet X. Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori. Clin Exp Gastroenterol. 2012;5:23–34.
Wang B, Wang Y-H, Lv Z-F, Xiong H-F, Wang H, Yang Y, et al. Review: efficacy and safety of hybrid therapy for Helicobacter pylori infection: a systematic review and meta-analysis. Helicobacter. 2015;20(2):79–88.
Li B-Z, Threapleton DE, Wang J-Y, Xu J-M, Yuan J-Q, Zhang C, et al. Comparative effectiveness and tolerance of treatments for Helicobacter pylori: systematic review and network meta-analysis. BMJ. 2015;351:h4052.
Fallone CA, Chiba N, van Zanten SV, Fischbach L, Gisbert JP, Hunt RH, et al. The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults. Gastroenterology. 2016;151(1):51-69.e14.
Basu PP, Rayapudi K, Pacana T, Shah NJ, Krishnaswamy N, Flynn M. A randomized study comparing levofloxacin, omeprazole, nitazoxanide, and doxycycline versus triple therapy for the eradication of Helicobacter pylori. Am J Gastroenterol. 2011;106(11):1970–5.
Kale-Pradhan PB, Mihaescu A, Wilhelm SM. Fluoroquinolone sequential therapy for helicobacter pylori: a meta-analysis. Pharmacotherapy. 2015;35(8):719–30.
Park C-S, Lee S-M, Park C-H, Koh H-R, Jun C-H, Park S-Y, et al. Pretreatment antimicrobial susceptibility-guided vs. clarithromycin-based triple therapy for Helicobacter pylori eradication in a region with high rates of multiple drug resistance. Am J Gastroenterol. 2014;109(10):1595–602.
Atehortua Rendon J, Pérez Cala T, Martínez A. Descripción de la resistencia de Helicobacter pylori a seis antibióticos de uso frecuente en Colombia. Rev Colomb de Gastroent. 2020;35(3):351-361.
Gisbert JP, Calvet X. Review article: rifabutin in the treatment of refractory Helicobacter pylori infection: Review: rifabutin for H. pylori infection. Aliment Pharmacol Ther. 2012;35(2):209–21.
Cheng H, Hu F-L. Furazolidone, amoxicillin, bismuth and rabeprazole quadruple rescue therapy for the eradication of Helicobacter pylori. World J Gastroenterol. 2009;15(7):860–4.
Liang X, Xu X, Zheng Q, Zhang W, Sun Q, Liu W, et al. Efficacy of bismuth-containing quadruple therapies for clarithromycin-, metronidazole-, and fluoroquinolone-resistant Helicobacter pylori infections in a prospective study. Clin Gastroenterol Hepatol. 2013;11(7):802-7.e1.
Vincentini O, De Angelis I, Stammati A, Zucco F. Functional alterations induced by the food contaminant furazolidone on the human tumoral intestinal cell line Caco-2. Toxicol In Vitro. 1993;7(4):403–6.
Graham D, Lu H. Furazolidone in Helicobacter pylori therapy: Misunderstood and often unfairly maligned drug told in a story of French bread. Saudi J Gastroent. 2012;18(1).
Shah S, Iyer P, Moss S. AGA Clinical Practice Update on the Management of Refractory Helicobacter pylori Infection: Expert Review. Gastroenterology. 2021;160(5):1831-1841.
Isaza C, Henao J, Martínez J, Arias J, Beltrán L. Phenotype-genotype analysis of CYP2C19 in Colombian mestizo individuals. BMC Clinical Pharmacology. 2007;7(1).
Murakami M, Sakurai Y, Shiino M, Funao N, Nisimura A, Asaka M. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. Gut. 2016;65(9):1439-46.
Nseir W, Diab H, Mahamid M, Abu-Elheja O, Samara M, Abid A, et al. Randomised clinical trial: simvastatin as adjuvant therapy improves significantly the Helicobacter pylori eradication rate--a placebo-controlled study. Aliment Pharmacol Ther. 2012;36(3):231–8.
Lau CSM, Ward A, Chamberlain RS. Probiotics improve the efficacy of standard triple therapy in the eradication of Helicobacter pylori: a meta-analysis. Infect Drug Resist. 2016;9:275–89.
Murakami K, Sakurai Y, Shiino M, Funao N, Nishimura A, Asaka M. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. Gut. 2016;65(9):1439–46.
Sezikli M, Çetinkaya ZA, Güzelbulut F, Yeşil A, Coşgun S, Kurdaş OÖ. Supplementing vitamins C and E to standard triple therapy for the eradication of Helicobacter pylori: Vitamin supplementation in the Helicobacter pylori treatment. J Clin Pharm Ther. 2012;37(3):282–5.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 CES Medicina
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Derechos de reproducción (copyright)
Cada manuscrito se acompañará de una declaración en la que se especifique que los materiales son inéditos, que no han sido publicados anteriormente en formato impreso o electrónico y que no se presentarán a ningún otro medio antes de conocer la decisión de la revista. En todo caso, cualquier publicación anterior, sea en forma impresa o electrónica, deberá darse a conocer a la redacción por escrito.
Plagios, duplicaciones totales o parciales, traduccones del original a otro idioma son de responsabilidad exclusiva de los autores el envío.
Los autores adjuntarán una declaración firmada indicando que, si el manuscrito se acepta para su publicación, los derechos de reproducción son propiedad exclusiva de la Revista CES Medicina.
Se solicita a los autores que proporcionen la información completa acerca de cualquier beca o subvención recibida de una entidad comercial u otro grupo con intereses privados, u otro organismo, para costear parcial o totalmente el trabajo en que se basa el artículo.
Los autores tienen la responsabilidad de obtener los permisos necesarios para reproducir cualquier material protegido por derechos de reproducción. El manuscrito se acompañará de la carta original que otorgue ese permiso y en ella debe especificarse con exactitud el número del cuadro o figura o el texto exacto que se citará y cómo se usará, así como la referencia bibliográfica completa.
| Article metrics | |
|---|---|
| Abstract views | |
| Galley vies | |
| PDF Views | |
| HTML views | |
| Other views | |
